Abstract
Background A global reduction in hospital admissions for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) was observed during the first months of the COVID-19 pandemic. Large-scale studies covering the entire pandemic period are lacking. We investigated hospitalizations for AECOPD and the associated in-hospital mortality at the national level in France during the first two years of the pandemic.
Methods We used the French National Hospital Database to analyse the time trends in (1) monthly incidences of hospitalizations for AECOPD, considering intensive care unit (ICU) admission and COVID-19 diagnoses, and (2) the related in-hospital mortality, from January 2016 to November 2021. Pandemic years were compared with the pre-pandemic years using Poisson regressions.
Results The database included 565,890 hospitalizations for AECOPD during the study period. The median age at admission was 74 years (interquartile range 65–83), and 37% of the stays concerned women. We found: (1) a dramatic and sustainable decline in hospitalizations for AECOPD over the pandemic period (from 8,899 to 6,032 monthly admissions, relative risk (RR) 0.65, 95% confidence interval (CI) 0.65–0.66), and (2) a concomitant increase in in-hospital mortality for AECOPD stays (from 6.2% to 7.6% per month, RR 1.24, 95% CI 1.21-1.27). The proportion of stays yielding ICU admission was similar in the pre-pandemic and pandemic years, 21.5% and 21.3%, respectively. In-hospital mortality increased to a greater extent for stays without ICU admission (RR 1.39, 95% CI 1.35–1.43) than for those with ICU admission (RR 1.09, 95% CI 1.05–1.13). Since January 2020, only 1.5% of stays were associated with a diagnosis of COVID-19, and their mortality rate was nearly 3-times higher than those without COVID-19 (RR 2.66, 95% CI 2.41–2.93).
Conclusion The decline in admissions for AECOPD during the pandemic could be attributed to a decrease in the incidence of exacerbations for COPD patients and/or to a possible shift from hospital to community care. The rise in in-hospital mortality is partially explained by COVID-19, and could be related to restricted access to ICUs for some patients and/or to greater proportions of severe cases among the patients hospitalized during the pandemic.
Competing Interest Statement
Christos Chouaid received payments from: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen
Funding Statement
The study was funded by the grant PREPS-20-0163 (Programme de recherche sur la performance du systeme des soins, French Ministry of Solidarity and Health).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In accordance with European and French regulations on data protection and ethics, the French Institute for Demographic Studies (INED) has carried out the required compliance formalities for access to administrative health databases. The French decree no. 2016-1871 of December 26, 2016 on the processing of personal data known as the Systeme national des donnees de sante (SNDS) has granted INED permanent access to the SNDS databases. All data of the SNDS are pseudonymised. Researchers and engineers affiliated with INED benefit from simplified access to data, on the condition that they follow the necessary training, respect the security measures outlined in the order of March 22, 2017 on the security framework applicable to the SNDS and accomplish any necessary procedures related to data protection compliance. Jonas Poucineau received authorization to access SNDS databases in 2021. The research was approved by INED s Data Protection Officer and registered in INED s records of processing activities under references 2021-DPD-0007. Jonas Poucineau s processing of SNDS data is considered compliant in terms of personal data protection and ethical research conduct.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The analysis described in this manuscript was performed in a national database (Programme de Medicalisation des Systemes d Information; PMSI) belonging to a third-party, namely the French Ministry of Health. Access to this database is available to researchers on reasonable demand, after proper training and upon request to the relevant agency, the Caisse Nationale d Assurance Maladie (CNAM), on condition that the analyses envisaged have been authorised by the French Data Protection Agency (Commission nationale de l Informatique et des Libertes, CNIL).
